Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $124

Wells Fargo analyst Derek Archila has maintained an Overweight rating on Disc Medicine (NASDAQ: IRON) and increased the price target from $86 to $124. This adjustment reflects a positive outlook for the company in the market.